KDM1A and acute myeloid leukemia: The LSD1 inhibitor (Tranylcypromine) can upregulate the expression of ULBP2/5/6 by promoting CCAAT/enhancer-binding protein α (C/EBPα) expression in acute myeloid leukemia (AML) cells, thereby increasing NK cells ability to lyse AML cells 71.